CureVac N.V.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company’s other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
/ 
Frequently asked questions
To buy CureVac N.V. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for CureVac N.V. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for CureVac N.V. is CVAC:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
CureVac N.V. has its primary listing on NASDAQ. You can trade CureVac N.V. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, CureVac N.V. is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include CureVac N.V. as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like CureVac N.V..